Reproductive Toxicity Induced by Serotonin‐Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database
CNS Neuroscience & Therapeutics · 2024-12 · 30 (12)
DOI: 10.1111/cns.70176 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.12.2024. Verfasst von Yujia Xi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Serotonin and Noradrenaline Reuptake Inhibitors, Adverse Drug Reaction Reporting Systems, Venlafaxine Hydrochloride. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation, "Four batches" of key projects of Shanxi Provincial Department of Science and Technology, Natural Science Foundation of Shanxi Province.
Abstract (Originalsprache)
Aim
Serotonin‐norepinephrine reuptake inhibitors (SNRIs) have been extensively utilized for the treatment of depression and anxiety disorders. Clinical trials and real‐world data suggest that SNRIs may cause reproductive toxicity. To comprehensively assess this association, we conducted a pharmacovigilance study.
Methods
We utilized various disproportionality analysis algorithms, including reporting odds ratio (ROR), proportional reporting ratio (PRR), bayesian confidence propagation neural network (BCPNN), and multi‐item gamma poisson shrinker (MGPS), to assess the significance of reproductive toxicity‐related adverse events (AEs) reported to FDA Adverse Event Reporting System (FAERS) from January 2004 to December 2023, with subgroup analysis conducted by sex and age.
Results
Duloxetine and venlafaxine were associated with 14 and 25 AE signals related to reproductive toxicity, respectively, with erectile dysfunction (ED) and retrograde ejaculation identified as shared important medical events (IMEs). ED had the highest reporting frequency, strongest in venlafaxine‐treated patients under 45 years (ROR 4.34, PRR 4.33, IC 2.09, EBGM 4.25). Retrograde ejaculation was newly identified. With decreasing incidence, venlafaxine's median ED onset was 122.5 days and duloxetine's 38 days.
Conclusion
Our study provides evidence through an extensive analysis of the large‐scale real‐world FAERS database, aiding healthcare professionals in mitigating, and prioritizing SNRI‐related reproductive toxicity AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Second Hospital of Shanxi Medical University, Taiyuan, China.
- Male Reproductive Medicine Center, Shanxi Medical University, Jinzhong, China.
- Department of Orthopedics, Second Hospital of Shanxi Medical University, Taiyuan, China.
ORCID-Profile: Zhuocheng Bao, Ke Yang
Förderung
- Wu Jieping Medical Foundation
- "Four batches" of key projects of Shanxi Provincial Department of Science and Technology
- Natural Science Foundation of Shanxi Province
- Shanxi Association for Science and Technology
Zitieren
APA
Xi, Y., Bao, Z., Guo, Q., Wang, J., Jing, Z., Di, J., & Yang, K. (2024). Reproductive Toxicity Induced by Serotonin‐Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database. CNS Neuroscience & Therapeutics, 30(12). https://doi.org/10.1111/cns.70176
Vancouver
Xi Y, Bao Z, Guo Q, Wang J, Jing Z, Di J, et al. Reproductive Toxicity Induced by Serotonin‐Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database. CNS Neuroscience & Therapeutics. 2024;30(12). doi:10.1111/cns.70176
BibTeX
@article{Xi2024,
author = {Xi, Yujia and Bao, Zhuocheng and Guo, Qiang and Wang, Jingqi and Jing, Zhinan and Di, Jingkai and Yang, Ke},
title = {Reproductive Toxicity Induced by Serotonin‐Norepinephrine Reuptake Inhibitors: A Pharmacovigilance Analysis From 2004 to 2023 Based on the FAERS Database},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {12},
doi = {10.1111/cns.70176}
}
EUVIMED